<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937559</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00021253</org_study_id>
    <nct_id>NCT01937559</nct_id>
  </id_info>
  <brief_title>Topical Tranexamic Acid (TXA) in Joint Arthroplasty</brief_title>
  <official_title>Topical Application of Tranexamic Acid in Joint Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hawkins Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hawkins Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in
      decreasing blood loss following both shoulder arthroplasty and primary total hip
      arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system
      within the body. The investigators hypothesize that topical application of TXA prior to
      closure reduces postoperative bleeding as measured by absolute changes in postoperative
      hemoglobin levels and surgical drain output. In addition, use of topically applied tranexamic
      acid may reduce the need for transfusions, the rates of hematomas, infections, and length of
      hospital stay.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Blood Loss</measure>
    <time_frame>Duration of hospital stay, up to 4 days</time_frame>
    <description>Blood loss will be calculated as the difference between the preoperative hemoglobin and the lowest postoperative hemoglobin during the hospital stay or the lowest postoperative hemoglobin prior to blood transfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perioperative Blood Transfusions</measure>
    <time_frame>Duration of hospital stay, up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Blood Units Transfused</measure>
    <time_frame>Duration of hospital stay, up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Surgical Infections</measure>
    <time_frame>Duration of hospital stay, up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Duration of hospital stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Outcomes Scores, Including Euroqol-5D (EQ-5D), Global Rating of Change Scale (GRoC), and Single Alpha Numeric Evaluation (SANE).</measure>
    <time_frame>6 months post-surgery</time_frame>
    <description>Single Assessment Numeric Evaluation (SANE): A single question that asks &quot;How would you rate your hip today as a percentage of normal (0% to 100% scale with 100% being normal)?&quot; 0 indicates an abnormal shoulder, whereas 100% indicates a perfectly normal shoulder.
Euroqol-5D (EQ-5D): The EQ-5D is a patient-reported overall health questionnaire, with 100 indicating &quot;The best health you can imagine&quot; and 0 indicating &quot;The worst health you can imagine.&quot;
Global Rating of Change Scale (GRoC): Provide a means of measuring self-perceived change in health status. The main purpose is to quantify the extent to which a patient has improved or deteriorated over time. The outcome is measured on a scale of -7 to 7, with -7 being the hip is &quot;a very great deal worse from before surgery&quot; and 7 being the hip is &quot;a very great deal better from before surgery.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Outcome Scores Including the Harris Hip Score and Western Ontario and McMaster Universities Arthritis Index (WOMAC)</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>Harris Hip Score: Consists of 10 question items evaluating pain, function, absence of deformity, and range of motion. Scores range from 0-100 with higher scores representing less dysfunction and better outcomes, whereas lower scores represent more dysfunction and worse outcomes.
Western Ontario and McMaster Universities Arthritis Index (WOMAC): Consists of 24 questions evaluating hip pain, stiffness and function. The score is normalized to a 100 point scale, where 0 indicates a poor outcome and 100 indicates the best outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Hip Arthropathy</condition>
  <condition>Shoulder Arthropathy</condition>
  <arm_group>
    <arm_group_label>Topical Tranexamic acid (TXA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic acid (TXA) applied topically</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid (TXA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tranexamic acid (TXA) administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tranexamic acid (TXA)</intervention_name>
    <description>1.5g of TXA in 100ml normal saline solution</description>
    <arm_group_label>Topical Tranexamic acid (TXA)</arm_group_label>
    <arm_group_label>Tranexamic acid (TXA)</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Shoulders: All adult patients over the age of 18 scheduled for a primary total
             arthroplasty or a primary reverse shoulder arthroplasty will be eligible for inclusion
             in the study.

        Hips: All adult patients over the age of 18 scheduled for a primary total hip arthroplasty
        will be eligible for inclusion in the study.

        Exclusion Criteria:

          -  allergy to TXA, refusal of blood products, preoperative use of anticoagulant therapy
             within 5 days of surgery, history of seizures, renal failure (creatine clearance
             &lt;30ml/min), bleeding disorders, venous thromboembolism (deep vein thrombosis and/or
             pulmonary embolism), significant cardiac history (myocardial infarction, angina,
             stroke, lower limb ischemia), or perioperative anemia (hemoglobin &lt;11g/dl in females
             and &lt; 12g/dl in males).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Burnikel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steadman Hawkins Clinic of the Carolinas - Greenville Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steadman Hawkins Clinic of the Carolinas - Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2013</study_first_posted>
  <results_first_submitted>April 10, 2020</results_first_submitted>
  <results_first_submitted_qc>April 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2020</results_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tranexamic acid (TXA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT01937559/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>122 patients were enrolled and randomized into one of two groups: tranexamic acid administered topically and saline administered topically (control). 61 patients were enrolled in each of the two groups. In addition, 66 patients who received tranexamic acid intravenously were retrospectively analyzed as a comparative group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Topical Tranexamic Acid (TXA)</title>
          <description>Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution administered topically</description>
        </group>
        <group group_id="P2">
          <title>Saline (Control)</title>
          <description>Normal saline administered topically (control)</description>
        </group>
        <group group_id="P3">
          <title>Intravenous Tranexamic Acid (TXA)</title>
          <description>Current standard of care is Tranexamic acid (TXA) administered intravenously. This arm was added as a retrospective comparative group, thus these patients were not randomized during the original study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>screen fail</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topical Tranexamic Acid (TXA)</title>
          <description>TXA administered topically
Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution administered topically</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Normal saline administered topically</description>
        </group>
        <group group_id="B3">
          <title>Intravenous Tranexamic Acid (TXA)</title>
          <description>Current standard of care is Tranexamic acid (TXA) administered intravenously. This arm was added as a retrospective comparative group, thus these patients were not randomized during the original study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="66"/>
            <count group_id="B4" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Several patients withdrew prior to primary endpoint being collected and thus were not included in analysis.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="66"/>
                    <count group_id="B4" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="35" upper_limit="86"/>
                    <measurement group_id="B2" value="65" lower_limit="40" upper_limit="87"/>
                    <measurement group_id="B3" value="65" lower_limit="35" upper_limit="83"/>
                    <measurement group_id="B4" value="64.2" lower_limit="35" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Several patients withdrew prior to primary endpoint being collected and thus were not included in analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="66"/>
                    <count group_id="B4" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Several patients withdrew prior to primary endpoint being collected and thus were not included in analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="66"/>
                    <count group_id="B4" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Several patients withdrew prior to primary endpoint being collected and thus were not included in analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="66"/>
                    <count group_id="B4" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>22 patients were withdrawn prior to surgery (11 in the Topical tranexamic acid group and 11 in the saline group). These patients were not included in the analysis population due to their pre-operative withdrawal from the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="66"/>
                    <count group_id="B4" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Blood Loss</title>
        <description>Blood loss will be calculated as the difference between the preoperative hemoglobin and the lowest postoperative hemoglobin during the hospital stay or the lowest postoperative hemoglobin prior to blood transfusion.</description>
        <time_frame>Duration of hospital stay, up to 4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Tranexamic Acid (TXA)</title>
            <description>Tranexamic acid (TXA) administered topically
Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Normal saline
Normal saline</description>
          </group>
          <group group_id="O3">
            <title>Intravenous Tranexamic Acid (TXA)</title>
            <description>Tranexamic acid (TXA) administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Blood Loss</title>
          <description>Blood loss will be calculated as the difference between the preoperative hemoglobin and the lowest postoperative hemoglobin during the hospital stay or the lowest postoperative hemoglobin prior to blood transfusion.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1,062.88" spread="338.78"/>
                    <measurement group_id="O2" value="1,204.60" spread="403.61"/>
                    <measurement group_id="O3" value="933.92" spread="351.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perioperative Blood Transfusions</title>
        <time_frame>Duration of hospital stay, up to 4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Tranexamic Acid (TXA)</title>
            <description>Tranexamic acid (TXA) administered topically
Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Normal saline
Normal saline</description>
          </group>
          <group group_id="O3">
            <title>Intravenous Tranexamic Acid (TXA)</title>
            <description>TXA administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perioperative Blood Transfusions</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Blood Units Transfused</title>
        <time_frame>Duration of hospital stay, up to 4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Tranexamic Acid (TXA)</title>
            <description>Topical Tranexamic acid (TXA)
Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Normal saline
Normal saline</description>
          </group>
          <group group_id="O3">
            <title>Intravenous Tranexamic Acid (TXA)</title>
            <description>Intravenous Tranexamic acid (TXA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Blood Units Transfused</title>
          <units>blood units</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Surgical Infections</title>
        <time_frame>Duration of hospital stay, up to 4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Tranexamic Acid (TXA)</title>
            <description>Tranexamic acid (TXA)
Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Normal saline
Normal saline</description>
          </group>
          <group group_id="O3">
            <title>Intravenous Tranexamic Acid (TXA)</title>
            <description>Intravenous Tranexamic acid (TXA)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Surgical Infections</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>Duration of hospital stay</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Tranexamic Acid (TXA)</title>
            <description>Topical Tranexamic acid (TXA)
Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Normal saline
Normal saline</description>
          </group>
          <group group_id="O3">
            <title>Intravenous Tranexamic Acid (TXA)</title>
            <description>Intravenous Tranexamic acid (TXA)</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.61"/>
                    <measurement group_id="O2" value="1.64" spread="0.72"/>
                    <measurement group_id="O3" value="1.39" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-reported Outcomes Scores, Including Euroqol-5D (EQ-5D), Global Rating of Change Scale (GRoC), and Single Alpha Numeric Evaluation (SANE).</title>
        <description>Single Assessment Numeric Evaluation (SANE): A single question that asks &quot;How would you rate your hip today as a percentage of normal (0% to 100% scale with 100% being normal)?&quot; 0 indicates an abnormal shoulder, whereas 100% indicates a perfectly normal shoulder.
Euroqol-5D (EQ-5D): The EQ-5D is a patient-reported overall health questionnaire, with 100 indicating &quot;The best health you can imagine&quot; and 0 indicating &quot;The worst health you can imagine.&quot;
Global Rating of Change Scale (GRoC): Provide a means of measuring self-perceived change in health status. The main purpose is to quantify the extent to which a patient has improved or deteriorated over time. The outcome is measured on a scale of -7 to 7, with -7 being the hip is &quot;a very great deal worse from before surgery&quot; and 7 being the hip is &quot;a very great deal better from before surgery.&quot;</description>
        <time_frame>6 months post-surgery</time_frame>
        <population>Patient-reported outcomes were only collected for the two randomized patient groups (Topical tranexamic acid and saline). Patient-reported outcomes were not collected on the intravenous tranexamic acid group, as this group was added for retrospective comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Tranexamic Acid (TXA)</title>
            <description>Topical Tranexamic acid (TXA)
Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Normal saline
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-reported Outcomes Scores, Including Euroqol-5D (EQ-5D), Global Rating of Change Scale (GRoC), and Single Alpha Numeric Evaluation (SANE).</title>
          <description>Single Assessment Numeric Evaluation (SANE): A single question that asks &quot;How would you rate your hip today as a percentage of normal (0% to 100% scale with 100% being normal)?&quot; 0 indicates an abnormal shoulder, whereas 100% indicates a perfectly normal shoulder.
Euroqol-5D (EQ-5D): The EQ-5D is a patient-reported overall health questionnaire, with 100 indicating &quot;The best health you can imagine&quot; and 0 indicating &quot;The worst health you can imagine.&quot;
Global Rating of Change Scale (GRoC): Provide a means of measuring self-perceived change in health status. The main purpose is to quantify the extent to which a patient has improved or deteriorated over time. The outcome is measured on a scale of -7 to 7, with -7 being the hip is &quot;a very great deal worse from before surgery&quot; and 7 being the hip is &quot;a very great deal better from before surgery.&quot;</description>
          <population>Patient-reported outcomes were only collected for the two randomized patient groups (Topical tranexamic acid and saline). Patient-reported outcomes were not collected on the intravenous tranexamic acid group, as this group was added for retrospective comparison.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EQ-5D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.87" spread="13.69"/>
                    <measurement group_id="O2" value="80.15" spread="16.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GRoC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" spread="0.91"/>
                    <measurement group_id="O2" value="5.54" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SANE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.06" spread="8.51"/>
                    <measurement group_id="O2" value="81.08" spread="21.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-reported Outcome Scores Including the Harris Hip Score and Western Ontario and McMaster Universities Arthritis Index (WOMAC)</title>
        <description>Harris Hip Score: Consists of 10 question items evaluating pain, function, absence of deformity, and range of motion. Scores range from 0-100 with higher scores representing less dysfunction and better outcomes, whereas lower scores represent more dysfunction and worse outcomes.
Western Ontario and McMaster Universities Arthritis Index (WOMAC): Consists of 24 questions evaluating hip pain, stiffness and function. The score is normalized to a 100 point scale, where 0 indicates a poor outcome and 100 indicates the best outcome.</description>
        <time_frame>6 months after surgery</time_frame>
        <population>Patient-reported outcomes were only collected for the two randomized patient groups (Topical tranexamic acid and saline). Patient-reported outcomes were not collected on the intravenous tranexamic acid group, as this group was added for retrospective comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Tranexamic Acid (TXA)</title>
            <description>Topical Tranexamic acid (TXA)
Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Normal saline
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-reported Outcome Scores Including the Harris Hip Score and Western Ontario and McMaster Universities Arthritis Index (WOMAC)</title>
          <description>Harris Hip Score: Consists of 10 question items evaluating pain, function, absence of deformity, and range of motion. Scores range from 0-100 with higher scores representing less dysfunction and better outcomes, whereas lower scores represent more dysfunction and worse outcomes.
Western Ontario and McMaster Universities Arthritis Index (WOMAC): Consists of 24 questions evaluating hip pain, stiffness and function. The score is normalized to a 100 point scale, where 0 indicates a poor outcome and 100 indicates the best outcome.</description>
          <population>Patient-reported outcomes were only collected for the two randomized patient groups (Topical tranexamic acid and saline). Patient-reported outcomes were not collected on the intravenous tranexamic acid group, as this group was added for retrospective comparison.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Harris Hip Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.03" spread="15.90"/>
                    <measurement group_id="O2" value="79.95" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.64" spread="15.42"/>
                    <measurement group_id="O2" value="13.46" spread="11.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from date of surgery to 6 month follow-up. All adverse events from the date of surgery to the final 6 month follow-up were assessed and collected for each patient.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Topical Tranexamic Acid (TXA)</title>
          <description>Topical Tranexamic acid (TXA)
Tranexamic acid (TXA): 1.5g of TXA in 100ml normal saline solution</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Normal saline
Normal saline</description>
        </group>
        <group group_id="E3">
          <title>Intravenous Tranexamic Acid (TXA)</title>
          <description>Intravenous Tranexamic acid (TXA)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ischemic stroke</sub_title>
                <description>ischemic stroke reported 8 months after surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kyle Adams, Research Coordinator</name_or_title>
      <organization>Hawkins Foundation</organization>
      <phone>864-454-7458</phone>
      <email>kyle.adams@hawkinsfoundation.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

